Liver Fibrosis - Pipeline Review, H2 2017

Global Markets Direct’s, ‘Liver Fibrosis - Pipeline Review, H2 2017’, provides an overview of the Liver Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Fibrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Liver Fibrosis

The report reviews pipeline therapeutics for Liver Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Liver Fibrosis therapeutics and enlists all their major and minor projects

The report assesses Liver Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Liver Fibrosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allergan Plc

Angion Biomedica Corp

Beijing Kawin Technology Share-Holding Co Ltd

BioLineRx Ltd

Bioneer Corp

BiOrion Technologies BV

Bird Rock Bio Inc

Bristol-Myers Squibb Company ...

Allergan Plc

Angion Biomedica Corp

Beijing Kawin Technology Share-Holding Co Ltd

BioLineRx Ltd

Bioneer Corp

BiOrion Technologies BV

Bird Rock Bio Inc

Bristol-Myers Squibb Company

Cellmid Ltd

ContraVir Pharmaceuticals Inc

Daiichi Sankyo Company Ltd

Dicerna Pharmaceuticals Inc

Dr. Falk Pharma GmbH

Dynavax Technologies Corp

Evotec AG

FibroGen Inc

Galectin Therapeutics Inc

Galmed Pharmaceuticals Ltd

Genfit SA

GenKyoTex SA

GNI Group Ltd

HanAll Biopharma Co Ltd

Immuron Ltd

Intercept Pharmaceuticals Inc

Isarna Therapeutics GmbH

KineMed Inc

Mission Therapeutics Ltd

Pfizer Inc

Pharmaxis Ltd

Promedior Inc

Promethera Biosciences SA

ProMetic Life Sciences Inc

Ribomic Inc

Samumed LLC

Silence Therapeutics Plc

Sirnaomics Inc

TaiwanJ Pharmaceuticals Co Ltd

TCM Biotech International Corp

TRACON Pharmaceuticals Inc

Vascular Biogenics Ltd

Virobay Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Liver Fibrosis - Overview 6

Liver Fibrosis - Therapeutics Development 7

Liver Fibrosis - Therapeutics Assessment 18

Liver Fibrosis ...

Table of Contents

Table of Contents 2

Introduction 5

Liver Fibrosis - Overview 6

Liver Fibrosis - Therapeutics Development 7

Liver Fibrosis - Therapeutics Assessment 18

Liver Fibrosis - Companies Involved in Therapeutics Development 30

Liver Fibrosis - Drug Profiles 48

Liver Fibrosis - Dormant Projects 193

Liver Fibrosis - Discontinued Products 196

Liver Fibrosis - Product Development Milestones 197

Appendix 207

List of Tables

List of Tables

Number of Products under Development for Liver Fibrosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products ...

List of Tables

Number of Products under Development for Liver Fibrosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Liver Fibrosis - Pipeline by Allergan Plc, H2 2017

Liver Fibrosis - Pipeline by Angion Biomedica Corp, H2 2017

Liver Fibrosis - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2017

Liver Fibrosis - Pipeline by BioLineRx Ltd, H2 2017

Liver Fibrosis - Pipeline by Bioneer Corp, H2 2017

Liver Fibrosis - Pipeline by BiOrion Technologies BV, H2 2017

Liver Fibrosis - Pipeline by Bird Rock Bio Inc, H2 2017

Liver Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2017

Liver Fibrosis - Pipeline by Cellmid Ltd, H2 2017

Liver Fibrosis - Pipeline by ContraVir Pharmaceuticals Inc, H2 2017

Liver Fibrosis - Pipeline by Daiichi Sankyo Company Ltd, H2 2017

Liver Fibrosis - Pipeline by Dicerna Pharmaceuticals Inc, H2 2017

Liver Fibrosis - Pipeline by Dr. Falk Pharma GmbH, H2 2017

Liver Fibrosis - Pipeline by Dynavax Technologies Corp, H2 2017

Liver Fibrosis - Pipeline by Evotec AG, H2 2017

Liver Fibrosis - Pipeline by FibroGen Inc, H2 2017

Liver Fibrosis - Pipeline by Galectin Therapeutics Inc, H2 2017

Liver Fibrosis - Pipeline by Galmed Pharmaceuticals Ltd, H2 2017

Liver Fibrosis - Pipeline by Genfit SA, H2 2017

Liver Fibrosis - Pipeline by GenKyoTex SA, H2 2017

Liver Fibrosis - Pipeline by GNI Group Ltd, H2 2017

Liver Fibrosis - Pipeline by HanAll Biopharma Co Ltd, H2 2017

Liver Fibrosis - Pipeline by Immuron Ltd, H2 2017

Liver Fibrosis - Pipeline by Intercept Pharmaceuticals Inc, H2 2017

Liver Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2017

Liver Fibrosis - Pipeline by KineMed Inc, H2 2017

Liver Fibrosis - Pipeline by Mission Therapeutics Ltd, H2 2017

Liver Fibrosis - Pipeline by Pfizer Inc, H2 2017

Liver Fibrosis - Pipeline by Pharmaxis Ltd, H2 2017

Liver Fibrosis - Pipeline by Promedior Inc, H2 2017

Liver Fibrosis - Pipeline by Promethera Biosciences SA, H2 2017

Liver Fibrosis - Pipeline by ProMetic Life Sciences Inc, H2 2017

Liver Fibrosis - Pipeline by Ribomic Inc, H2 2017

Liver Fibrosis - Pipeline by Samumed LLC, H2 2017

Liver Fibrosis - Pipeline by Silence Therapeutics Plc, H2 2017

Liver Fibrosis - Pipeline by Sirnaomics Inc, H2 2017

Liver Fibrosis - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2017

Liver Fibrosis - Pipeline by TCM Biotech International Corp, H2 2017

Liver Fibrosis - Pipeline by TRACON Pharmaceuticals Inc, H2 2017

Liver Fibrosis - Pipeline by Vascular Biogenics Ltd, H2 2017

Liver Fibrosis - Pipeline by Virobay Inc, H2 2017

Liver Fibrosis - Dormant Projects, H2 2017

Liver Fibrosis - Dormant Projects, H2 2017 (Contd..1), H2 2017

Liver Fibrosis - Dormant Projects, H2 2017 (Contd..2), H2 2017

Liver Fibrosis - Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Liver Fibrosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products ...

List of Figures

Number of Products under Development for Liver Fibrosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports